How clinical trials can bounce back
“COVID-19 has demonstrated that sponsors and investigators can achieve in weeks what was previously thought to require months or years,” write six biopharmaceutical business consultants. They suggest five actions that researchers can take to address the ongoing challenges for disrupted clinical trials and ongoing patient care. Rod MacKenzie and four colleagues from US pharmaceutical company Pfizer agree that lessons learnt from coronavirus-vaccine development should be brought to bear on other diseases. “We should seize this moment, before our conventions re-solidify to the old ways of doing things, to embed the improvements made during the COVID-19 pandemic and accelerate others, on behalf of all patients,” they argue.
Nature Reviews Drug Discovery | 6 min read & Nature Reviews Drug Discovery | 7 min readRead more: Coronavirus shuts down trials of drugs for multiple other diseases (Nature | 6 min read, from March)
No hay comentarios:
Publicar un comentario